Reduction of hypokalaemia with finerenone: a drug or class-specific effect?
作者信息
Rosano Giuseppe M C, Ono Koh, Imbalzano Egidio, Hasegawa Koji
机构信息
Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome, via di val cannuta, Rome 00163, Italy.
Cardiology, San Raffaele Cassino Hospital, Via Gaetano di Biasio, 1, Cassino FR 03043, Italy.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):20-21. doi: 10.1093/ehjcvp/pvae089.
Abstract
摘要
相似文献
1
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?非奈利酮降低低钾血症：是药物特异性效应还是类别特异性效应？
Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):20-21. doi: 10.1093/ehjcvp/pvae089.
2
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis.2型糖尿病合并慢性肾脏病患者的低钾血症：非奈利酮的影响——一项FIDELITY分析
Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):10-19. doi: 10.1093/ehjcvp/pvae074.
3
Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial.
JACC Heart Fail. 2025 Apr 2:102440. doi: 10.1016/j.jchf.2025.03.007.
4
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.非奈利酮、肥胖与射血分数轻度降低/保留的心力衰竭：FINEARTS-HF的预设分析
J Am Coll Cardiol. 2025 Jan 21;85(2):140-155. doi: 10.1016/j.jacc.2024.10.111. Epub 2024 Dec 10.
5
Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.体外和体内药物相互作用研究的结果，研究非奈利酮对药物转运蛋白 BCRP、OATP1B1 和 OATP1B3 的抑制作用。
Eur J Drug Metab Pharmacokinet. 2022 Nov;47(6):803-815. doi: 10.1007/s13318-022-00794-5. Epub 2022 Aug 27.
6
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.非奈利酮治疗糖尿病肾病患者蛋白尿的疗效：一项随机临床试验。
JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.
7
Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications.药物相互作用的体外和体内研究结果，研究了非奈利酮对合并用药药代动力学的影响。
Eur J Drug Metab Pharmacokinet. 2020 Aug;45(4):433-444. doi: 10.1007/s13318-020-00610-y.
8
Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.非奈利酮和胰高血糖素样肽-1受体激动剂对2型糖尿病患者心血管和肾脏结局的影响：一项系统评价和荟萃分析
Diabetol Metab Syndr. 2024 Jan 11;16(1):14. doi: 10.1186/s13098-023-01251-2.
9
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.非奈利酮与心力衰竭患者新发糖尿病：FINEARTS-HF试验的一项预设分析
Lancet Diabetes Endocrinol. 2025 Feb;13(2):107-118. doi: 10.1016/S2213-8587(24)00309-7. Epub 2025 Jan 13.
10
Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.非甾体类盐皮质激素受体拮抗剂在糖尿病肾病患者中的疗效
Postgrad Med. 2023 Apr;135(3):224-233. doi: 10.1080/00325481.2022.2060598. Epub 2022 Apr 20.
本文引用的文献
1
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis.2型糖尿病合并慢性肾脏病患者的低钾血症：非奈利酮的影响——一项FIDELITY分析
Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):10-19. doi: 10.1093/ehjcvp/pvae074.
2
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.低钾血症的管理更新及心血管疾病患者更低血钾水平的目标：与欧洲心脏病学会心血管药物治疗工作组合作进行的综述
Eur Heart J Cardiovasc Pharmacother. 2021 Nov 3;7(6):557-567. doi: 10.1093/ehjcvp/pvab038.
3
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.专家共识文件：血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂治疗的心血管疾病患者的高钾血症管理：由欧洲心脏病学会心血管药理学工作组协调。
Eur Heart J Cardiovasc Pharmacother. 2018 Jul 1;4(3):180-188. doi: 10.1093/ehjcvp/pvy015.
Zotero 插件